NCT00542529已完成1 期
Phase I/II, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Single-Center Study of the Progenitor Cell Mobilizing Effects of Imprime PGG™ Injection Administered at Varied Dosing Regimens With G-CSF Versus G-CSF Alone in Healthy Subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 66
- 主要终点
- -To determine the safety of Imprime PGG when dosed as part of a standard 4-day regimen of G-CSF assessed via occurrence of adverse events and change from baseline in clinical laboratories, physical examination, vital signs and ECG
研究概览
简要总结
This study is a randomized, placebo-controlled, dose-escalation, single-center study evaluating two different doses of Imprime PGG, each in 7 different dosing regimes. A total of 66 subjects will be enrolled into 2 cohorts and, within each cohort, randomized to 1 of 7 treatment groups receiving Imprime PGG or placebo in varied dosing regimens with granulocyte-colony stimulating factor (G-CSF).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Be between the ages of 18 and 45, inclusive
- •Have a body weight of 45 kg to 125 kg, inclusive, and a body mass index less than or equal to 30 kg/m2
- •Be healthy based on medical history, physical examination, electrocardiogram (ECG), and clinical laboratory test results
- •If female, be non-pregnant and non-nursing. For either gender, the subject must be either sexually inactive (14 days prior to the first dose of study drug and throughout the study) or practicing at least two methods of birth control from the following list of acceptable forms of contraception:
- •Surgically sterile subject or partner (bilateral tubal ligation, hysterectomy, bilateral oophorectomy or vasectomy performed at least 6 months prior to first dose of study drug)
- •Intrauterine device (IUD) in place for at least 3 months
- •Barrier methods (condom, diaphragm) with spermicide from the time of the subject/partner's last menstrual period and throughout the study
- •Hormonal contraceptives for at least 3 months prior to the first dose of study drug
- •Has read, understood and signed the IRB-approved informed consent form (ICF)
排除标准
- •Has a known hypersensitivity to baker's yeast, G-CSF, or E.coli-derived proteins, or has an active yeast infection
- •Has any clinical condition that, in the opinion of the investigator, warrants exclusion from the study from a scientific, procedural, or safety perspective
- •Has a history of tobacco use within 90 days of the last day of screening (Day -1) or be a known or suspected abuser of alcohol or other drugs/substances of abuse
- •Has a positive hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) test conducted as part of screening
- •Except as otherwise indicated, has taken any prescription medication within 30 days of the last day of screening (Day -1) or over-the-counter medication, herbal preparation, or vitamins within 7 days of the last day of screening (Day -1)
- •Has participated in an investigational drug study within 30 days or five half-lives (whichever is longer) of the last day of screening (Day -1), has received G-CSF within 30 days of the last day of screening, or has ever participated in a study with Imprime PGG or Betafectin®
- •Has donated or lost more than a unit of blood within 30 days of the last day of screening (Day -1)
结局指标
主要结局
-To determine the safety of Imprime PGG when dosed as part of a standard 4-day regimen of G-CSF assessed via occurrence of adverse events and change from baseline in clinical laboratories, physical examination, vital signs and ECG
时间窗: Prospective
次要结局
- -To evaluate the progenitor cell mobilizing efficacy of Imprime PGG when dosed as part of a standard 4-day progenitor cell mobilizing regimen of G-CSF assessed through peripheral blood CD34+ cell counts(Prospective)
研究者
相似试验
已完成
1 期
A Study of rhuMAb IFNalpha in Adults With Systemic Lupus ErythematosusSystemic Lupus ErythematosusNCT00541749Genentech, Inc.60
已完成
1 期
A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001) Injected to Elderly VolunteersInfluenzaNCT01010737BiondVax Pharmaceuticals ltd.60
已完成
1 期
A Phase I Study of ICP-022 in Healthy SubjectsSystemic Lupus ErythematosusRheumatoid ArthritisNCT03189017Innocare Pharma Australia Pty Ltd64
已完成
1 期
Study to Assess the Safety, Tolerability and Pharmacokinetics of STI-1558 in Healthy VolunteersCOVID-19NCT05364840Sorrento Therapeutics, Inc.58
已完成
1 期
Phase 1/2 Study to Evaluate the Efficacy and Safety of Inhaled IBIO123 in Participants With Mild to Moderate COVID-19 IllnessCOVID-19NCT05298813Immune Biosolutions Inc162